Review: β-blockers increase fatigue and sexual dysfunction but not depression after myocardial infarction

Ko, Dennis T.; Hebert, Patricia R.; Krumholz, Harlan M.; Swann, Alan C.
January 2003
ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p30
Academic Journal
Comments on a study which investigated the nocebo effect and the side effects of placebo. Argument on the association between β-blockers and substantial risks for the side effects of placebo; Response to the comments.


Related Articles

  • Beta-Blocking Agents and Electroconvulsive Therapy. van den Broek, Walter W.; Groenland, Theo H. N.; Mulder, Paul G. H.; Kusuma, Ari; Birkenhäger, Tom K.; Pluijms, Esther; Bruijn, Jan A. // Current Drug Therapy;May2007, Vol. 2 Issue 2, p121 

    In this review we want to summarize the results of the placebo-controlled randomized clinical trials with betablocking adrenergic agents during electroconvulsive therapy (ECT), and review the effect on seizure duration and cardiovascular variables. We searched for studies in the electronic...

  • A short review of the I-f Channel Antagonist, Ivabradine. Chatterjee, Saurav // Internet Journal of Cardiology;2008, Vol. 6 Issue 2, p1 

    Ivabradine is a selective sinus node inhibitor which decreases resting heart rate. It is licensed for the treatment of chronic stable angina in patients with normal sinus rhythm, who have a contraindication or intolerance for beta blockers. In five clinical efficacy studies, ivabradine has been...

  • Oral Administration of Nipradilol and the Acute and Chronic Splanchnic Hemodynamic Effects of a New &beta:-Blocker with Nitrovasodilating Properties in Patients with Liver Cirrhosis. Sugano, Shigeo; Kawafune, Takashi; Suzuki, Tokuya; Kubota, Manabu; Okajima, Tugio; Sumino, Yasukiyo; Akita, Hiroaki // American Journal of Gastroenterology;May1995, Vol. 90 Issue 5, p788 

    Objectives: We studied the effects of nipradilol, which has both a nonselective β-blocker action and a vasodilating action similar to nitroglycerin, on portal hypertension. Methods: We measured hepatic venous pressure gradient and splanchnic and systemic hemodynamics before beginning therapy,...

  • COMMENTARY: Physical counterpressure maneuvers reduced vasovagal syncope. Evans, Arthur T. // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p41 

    The article presents the author's views about a study which states that physical counter pressure maneuvers reduced vasovagal syncope. Treatments focused on the bradycardia have proven ineffective in rigorous studies. Treatments designed to counteract the peripheral vasodilation are potentially...

  • Beta-blockers no better than placebo in the treatment of vasovagal syncope. Phillips, John; Krist, Alex // Journal of Family Practice;Nov2002, Vol. 51 Issue 11, p921 

    The article presents research which dealt with the efficiency of beta blockers in the treatment of vasovagal syncope. This research was designed to be unblinded, crossover placebo-controlled trial. It concluded that overall, no difference was observed the in the number of syncopal episodes or...

  • Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and �-Blockers in the Treatment of Patients With Heart Failure. Hennekens, Charles H.; Kowalczykowski, Magda; Hollar, Danielle // Journal of Cardiovascular Pharmacology & Therapeutics;Jun2006, Vol. 11 Issue 2, p149 

    Examines the lack of deleterious interaction between angiotensin receptor blockers and ?-blockers in heart failure patients. Overview of the U.S. Food and Drug Administration-approved heart failure indication for candesartan; Trial to test whether candesartan reduced risk of cardiovascular...

  • Intrinsic Sympathomimetic Activity Counteracts Beta-Blocker Inhibition of Renin Activation. Ruddy, Michael C.; Bialy, Grace B.; Kostis, John B. // Angiology;Jan1989, Vol. 40 Issue 1, p45 

    Enzymatically inactive renin (IR) is the predominant circulating form of renin. Sympathetic activity may influence plasma renin activity (PRA) by regulation of the conversion of IR to active renin (AR, PRA). It has been demonstrated previously that beta blockade lowers PRA at least partly...

  • Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Conraads, Viviane M.; Metra, Marco; Kamp, Otto; De Keulenaer, Gilles W.; Pieske, Burkert; Zamorano, Jos�; Vardas, Panos E.; B�hm, Michael; Dei Cas, Livio // European Journal of Heart Failure;Feb2012, Vol. 14 Issue 2, p219 

    Aims We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, could favourably affect exercise capacity in patients with heart failure and preserved left ventricular ejection fraction (HFPEF). Methods and results A total of 116 subjects with HFPEF, in New York Heart...

  • Mirabegron -- a selective �3-adrenoreceptor agonist for the treatment of overactive bladder. Bhide, Alka A.; Digesu, G. Alessandro; Fernando, Ruwan; Khullar, Vik // Research & Reports in Urology;2012, Issue 4, p41 

    Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics